Skip to main content

Table 1 Comparison of patient’s clinical characteristics at baseline between the ABT and JAKi groups

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

 

ABT

JAKi

p value

Number of patients

45

26

 

Gender, female (%)

29 (64.4)

18 (69.2)

0.797

Age, years

74 (71–81)

74 (70–79)

0.384

ILD, n (%)

  

0.002

UIP

23 (51.1)

4 (15.4)

 

NSIP

22 (48.9)

20 (76.9)

 

Unclassifiable

0 (0.0)

2 (7.7)

 

ABT, n (%)

   

Subcutaneous injection

36 (0.8)

-

 

Intravenous drip

9 (0.2)

-

 

JAKi, n (%)

   

Tofacitinib

-

16 (61.5)

 

Baricitinib

-

10 (38.5)

 

Disease duration, years

6 (3–18)

17 (7–25)

0.024

Stage ≥ III, n (%)

20 (44.4)

14 (53.9)

0.471

Class ≥ 3, n (%)

4 (8.9)

1 (3.9)

0.646

ACPA positive, n (%)

40 (88.9)

26(100)

0.151

ACPA ≥ 100, n (%)

28 (62.2)

19 (73.1)

0.439

RF positive, n (%)

40 (88.9)

26 (100)

0.151

RF ≥ 100, n (%)

28 (62.2)

19 (73.1)

0.439

DAS28-CRP

4.37 (3.91–5.21)

4.35 (3.26–5.58)

0.919

mHAQ

0.81 (0.13–1.13)

0.63 (0.10–1.41)

0.852

Past use of bDMARDs or JAKi, n (%)

13 (28.9)

21 (80.8)

< 0.001

Most recent bDMARDs or JAKi, n (%)

  

0.057

IL6i

6 (46.2)

8 (33.3)

 

CTLA4-ig

-

7 (38.1)

 

TNFi

6 (46.2)

6 (28.6)

 

JAKi

1 (7.7)

0 (0.0)

 

Methotrexate, n (%)

14 (31.1)

6 (23.1)

0.588

Prednisolone, n (%)

31 (68.9)

19 (73.1)

0.792

Prednisolone dose, mg/day

4.0 (0.0–5.0)

4.5 (2.5–6.0)

0.405

Smoking, n (%)

  

0.381

Never

31 (68.9)

18 (69.2)

 

Ex-smoker

8 (17.8)

2 (7.7)

 

Current smoker

6 (13.3)

6 (23.1)

 

Diabetes mellitus, n (%)

7 (15.6)

3 (11.5)

0.736

  1. Data are presented as number of patients (%) or the median value (interquartile range)
  2. ABT: abatacept; JAKi: Janus kinase inhibitor; ILD: interstitial lung disease; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; ACPA: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; DAS28-CRP: disease activity score 28-C-reactive protein; mHAQ: modified health assessment questionnaire; bDMARD: biological disease modifying anti-rheumatic drugs; IL6i: anti-inteleukin-6 inhibitors; CTLA4-ig: cytotoxic T lymphocyte-associated antigen-4-immunoglobulin; TNFi: anti-TNFα inhibitors
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us